Childhood blepharokeratoconjunctivitis: Characterising a severe phenotype in white adolescents

British Journal of Ophthalmology

Volumn 96, Issue 7, 2012, Pages 949-955

  Hamada, Samer ^a   Khan, Imran ^a   Denniston, Alastair K ^a   Rauz, Saaeha ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DEXAMETHASONE; DOXYCYCLINE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; STEROID; TETRACYCLINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BLEPHAROKERATOCONJUNCTIVITIS; CAUCASIAN; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORNEA PERFORATION; CORNEA VASCULARIZATION; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS; MALE; PHENOTYPIC VARIATION; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT PLANNING; VISUAL ACUITY;

ADOLESCENT; ADULT; AZATHIOPRINE; BLEPHARITIS; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS; MALE; MYCOPHENOLIC ACID; PHENOTYPE; PREDNISOLONE; VISUAL ACUITY; YOUNG ADULT;

EID: 84862897785     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300771     Document Type: Article

References (27)

1. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1987;89:1173-80. (Pubitemid 12003236)
2. Bernardes TF, Bonfioli AA. Blepharitis. Semin Ophthalmol 2010;25:79-83.
3. Viswalingam M, Rauz S, Mortlet N, et al. Blepharoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol 2005;89:400-3.
4. Wilhelmus KR. Inflammatory disorders of the eye lid margins and lashes. Ophthalmol Clin North Am 1992;5:187.
5. Farpour B, McClellan KA. Diagnosis and management of chronic blepharoconjunctivitis in children. J Paediatr Ophthalmol Strabismus 2001;38:204-12.
6. Doan S, Gabison EE, Nghiem-Buffet S, et al. Long-term visual outcome of childhood blepharokeratoconjunctivitis. Am J Ophthalmol 2007;143:528-9.
7. Jones SM, Weinstein JM, Cumberland P, et al. Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology 2007;114:2271-80. (Pubitemid 350181090)
8. Elder MJ, Bernauer W. Monitoring of activity and progression in cicatrizing conjunctivitis. Dev Ophthalmol 1997;28:111-22.
9. Sotozona C, Ang LP, Koizuma N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007;114:1294-302. (Pubitemid 47001496)
10. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf 2003;1:107-26. (Pubitemid 41263900)
11. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011;52:1922-9.
12. Hammersmith KM, Cohen EJ, Blake TD, et al. Blepharokeratoconjunctivitis in children. Arch Ophthalmol 2005;123:1667-70. (Pubitemid 41785099)
13. Gupta N, Dhawan A, Beri S, et al. Clinical spectrum of pediatric blepharokeratoconjunctivitis. J AAPOS 2010;14:527-9.
14. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004;137:138-44. (Pubitemid 38045200)
15. Meisler DM, Raizman MB, Traboulsi EI. Oral erythromycin treatment for childhood blepharokeratitis. J AAPOS 2000;4:379-80.
16. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratonconjunctivitis. Curr Med Res Opin 2008;24:287-96. (Pubitemid 351181204)
17. Auw-Hädrich C, Reinhard T. Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe 2009;106:635-8.
18. Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24:417-20. (Pubitemid 40586629)
19. Cehajic-Kapetanovic J, Kwartz J. Augmentin duo in the treatment of childhood blepharokeratoconjunctivitis. J Pediatr Ophthalmol Strabismus 2010;8:1-5.
20. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci 2011;52:2050-64.
21. Aronomwicz JD, Shine WE, Oral D, et al. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol 2006;90:856-60. (Pubitemid 43973996)
22. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003;22:545-8. (Pubitemid 36909734)
23. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000;41:2544-57. (Pubitemid 30624381)
24. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL1beta, TNF-alpha and IL -8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006;82:588-96. (Pubitemid 43122089)
25. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003;47:3630-3. (Pubitemid 37345735)
26. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991;51:672-5.
27. Pflugfelder SC. Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5:163-78. (Pubitemid 351902655)